|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
Original paper
COVID-19 restrictions’ impact on epidemiology of respiratory syncytial virus in south-eastern Poland
Wojciech Kmiecik
1
,
Krzysztof Batko
2
,
Nikola Król
3
,
Kamila Kędra
3
,
Aleksandra Łoś
3
,
Izabela Michalik
3
,
Piotr Sajdak
3
,
Paweł Zapolnik
4
,
Hanna Czajka
4
Pediatr Pol 2026; 101 (1)
Online publish date: 2026/03/20
Article file
- COVID-19 restrictions.pdf
[0.21 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics . Lancet Respir Med 2015; 3: 888-900. 2.
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399: 2047-2064. 3.
Di Mattia G, Nenna R, Mancino E, Rizzo V, Pierangeli A, Villani A, et al. During the COVID-19 pandemic where has respiratory syncytial virus gone? Pediatr Pulmonol 2021; 56: 3106-3109. 4.
Varela FH, Scotta MC, Polese-Bonatto M, Sauthier Sartor IT, Ferreira CF, Fernandes IR, et al. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: likely role of lower transmission in the community. J Glob Health 2021; 11: 05007. 5.
Van Brusselen D, De Troeyer K, Ter Haar E, Vander Auwera A, Poschet K, van Nuijs S, et al. Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr 2021; 180: 1969-1973. 6.
Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T, et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health 2020; 4: 622. 7.
Curatola A, Lazzareschi I, Bersani G, Covino M, Gatto A, Chiaretti A. Impact of COVID-19 outbreak in acute bronchiolitis: lesson from a tertiary Italian Emergency Department. Pediatr Pulmonol 2021; 56: 2484-2488. 8.
Eden JS, Sikazwe C, Xie R, Deng YM, Sullivan SG, Michie A, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun 2022; 13: 2884. 9.
Hussain F, Kotecha S, Edwards MO. RSV bronchiolitis season 2021 has arrived, so be prepared! Arch Dis Child 2021; 106: e51. 10.
Tempia S, Walaza S, Bhiman JN, McMorrow ML, Moyes J, Mkhencele T, et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill 2021; 26: 2001600. 11.
Delestrain C, Danis K, Hau I, Behillil S, Billard MN , Krajten L, et al. Impact of COVID-19 social distancing on viral infection in France: A delayed outbreak of RSV. Pediatr Pulmonol 2021; 56: 3669-3673. 12.
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540. 13.
Wrotek A, Czajkowska M, Jackowska T. Seasonality of respiratory syncytial virus hospitalization. Adv Exp Med Biol 2020; 1279: 93-100. 14.
Hatami H, Qaderi S, Shah J, Rezaeian AR, Farsi Y, Alinasab F, et al. National pandemic management strategies and their efficacies and impacts on the number of secondary cases and prognosis: a systematic review. Int J Prev Med 2022; 13: 100. 15.
Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics 2021; 148: e2021052089. 16.
Torres AR, Guiomar RG, Verdasca N, Melo A, Rodrigues AP; Rede Portuguesa de Laboratórios para o Diagnóstico da Gripe. Resurgence of respiratory syncytial virus in children: an out-of-season epidemic in Portugal. Acta Med Port 2023; 36: 343-352. 17.
Otomaru H, Kamigaki T, Tamaki R, Okamoto M 1 , Alday PP, Gue Tan A, et al. Transmission of respiratory syncytial virus among children under 5 years in households of rural communities, the Philippines. Open Forum Infect Dis 2019; 6: ofz045. 18.
Pogonowska M, Guzek A, Gościńska A, Rustecka A, Kalicki B, et al. Compensatory epidemic of RSV infections during the COVID-19 pandemic. An analysis of infections in children hospitalised in the Department of Paediatrics, Paediatric Nephrology and Allergology of the Military Medical Institute in Warsaw in 2020–2021. Pediatr Med Rodz 2022; 18: 52-57. 19.
Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A 2020; 117: 30547-30553. 20.
Garg I, Shekhar R, Sheikh AB, Pal S. Impact of COVID-19 on the changing patterns of respiratory syncytial virus infections. Infect Dis Rep 2022; 14: 558-568. 21.
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588-598. 22.
Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PAJ, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004; 89: 673-678. 23.
European Medicines Agency. Synagis. Available online: https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_en.pdf (accessed: 10.12.2023). 24.
European Medicines Agency. New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection. Available online: https://www.ema.europa.eu/en/news/new-medicine-protect-babies-infants-respiratory-syncytial-virus-rsv-infection (accessed: 10.12.2023). 25.
AstraZeneca. Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants. Available online: https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint.html (accessed: 10.12.2023). 26.
Hammitt LL, Dagan R, Yuan Y, Manuel Baca Cots 1 , Miroslava Bosheva 1 , Shabir A Madhi 1 , et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022; 386: 837-846. 27.
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzo- ni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383: 415-425. 28.
Medicines & Healthcare products Regulatory Agency. Nirsevimab (Beyfortus): UK prescribing information. Available online: https://products.mhra.gov.uk/search/?search=NIRSEVIMAB&page=1&doc=Spc%7CPar&ter=GB&rerouteType=0 (accessed: 10.12.2023). 29.
Helwich E, Miszczak-Knecht M, Sands D, Emich-Widera E. Expanding the indications for the prevention of severe respiratory syncytial virus (RSV) infections with palivizumab in newborns and infants – experts’ position statement. Stand Med. Pediatr 2022; 19: 549-555. 30.
Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Lla- pur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388: 1451-1464. 31.
Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med 2022; 386: 1615-1626.
Copyright: © 2026 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
POLSKI
